

**PROPOSED REGULATION OF THE  
STATE BOARD OF PHARMACY**

**LCB FILE NO. R198-18I**

**The following document is the initial draft regulation proposed  
by the agency submitted on 12/26/2018**

# Proposed Regulation of the Nevada State Board of Pharmacy

Workshop December 5, 2018

Explanation – Language in *blue italics* is new; language in *red text* [~~omitted material~~] is language to be omitted, and language in *green text* indicates prior Board-approved amendments that are in the process of being codified.

AUTHORITY: §1, NRS 639.070

**A REGULATION relating to controlled substances; adding certain substances to the controlled substances listed in Schedule V; and providing other matters properly relating thereto.**

## **NAC 453.550 Schedule V. (NRS 453.146, 639.070)**

1. Schedule V consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.
2. Any compound, mixture or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base alkaloid, containing one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone, in quantities:
  - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
  - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
  - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
  - (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
  - (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or

(f) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

3. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pyrovalerone having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers.

4. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pregabalin having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers.

5. Lacosamide.

*6. Cannabidiol; Epidiolex; (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) in a drug product that has been approved by the U.S Food and Drug that is derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.*